Clinical research of advanced nasopharyngeal carcinoma patients treated by Apatinib mesylate tables: a second line therapeutical research.
Latest Information Update: 16 Mar 2017
At a glance
- Drugs Rivoceranib (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 16 Mar 2017 New trial record